{"url_path":"/sec/lxeo/8-k/2026-06-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1907108/0001193125-26-270275-index.html","accession_number":"0001193125-26-270275","cik":"0001907108","ticker":"LXEO","issuer_name":"Lexeo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1907108/0001193125-26-270275-index.html","primary_entity_key":"0001907108","primary_entity_name":"Lexeo Therapeutics, Inc."},"word_count":101,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\n \n\nThe corporate presentation to be used in connection with the webcast described in Item 8.01 below is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.\n\nThe information in this Item 7.01, including Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing."}